Company Summary
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC.
On a geographical basis, the company has operations in the North America (47% of 2023 net revenues), Western Europe (16%), other developed markets (5%) and high-growth markets (32%). Exiting 2023, it has an employee base of 63,000 people. The company’s segmental details are provided below:
Diagnostics (40.1% of revenues generated in 2023) segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps ...
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC.
On a geographical basis, the company has operations in the North America (47% of 2023 net revenues), Western Europe (16%), other developed markets (5%) and high-growth markets (32%). Exiting 2023, it has an employee base of 63,000 people. The company’s segmental details are provided below:
Diagnostics (40.1% of revenues generated in 2023) segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps diagnose diseases and make suitable treatment decisions.
Life Sciences (29.9%) segment provides a broad range of research tools used to analyze a range of critical areas — including genes, proteins, metabolites and cells — to understand the causes of diseases, identify new therapies and test new drugs and vaccines. The range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. In addition, the segment offers products and consumables that are designed to filter and remove contaminants from various liquids and gases in several end-market applications.
Biotechnology (30%) segment includes bioprocessing and discovery and medical businesses. It provides a wide range of tools, consumables and services utilized in the research, development, manufacturing and delivery process of biological medicines. The company’s solutions support biotherapeutics that range from replacement therapies like vaccines, insulin, recombinant proteins and other biological drugs to mRNA, novel cell, gene and other nucleic acid therapies.
In September 2023, the company spun off its Environmental & Applied Solutions segment into an independent public company. The separation helps Danaher focus more on its core Life Sciences and Biotechnology segments.